ICON Public Limited Company's Audit Committee is investigating accounting practices and internal controls related to revenue recognition from fiscal years 2023-2025. The company disclosed material weaknesses in internal controls, delayed financial results, and withdrew 2025 guidance. ICON shares fell approximately 40% on the announcement, declining from $133.14 to $80.08 per share on February 12, 2026.

The FDA granted Breakthrough Therapy Designation to Johnson & Johnson's Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for treating advanced, HPV-unrelated head and neck squamous cell carcinoma in adults. The drug is being evaluated in combination with Merck's Keytruda in an ongoing Phase 3 trial. Additionally, J&J extended its contract with Trellus Health for patient support services through mid-2026.

The global clinical trials support software solutions market is valued at USD 14.31 billion in 2026 and is expected to reach USD 34.15 billion by 2035, growing at a 10.15% CAGR. North America leads the market while Asia Pacific shows the fastest growth. CTMS solutions dominate by product type, cloud-based delivery leads, and CROs lead by end-user segment. Key growth drivers include increasing clinical trial complexity, adoption of decentralized trials, AI-driven analytics, and regulatory compliance demands.

Block & Leviton is investigating Gemini Space Station, Inc. (GEMI) for potential securities law violations after the company's stock fell over 10% following the sudden departure of multiple senior executives including its COO, CFO, and Chief Legal Officer. This leadership shakeup occurred months after the company's September 2025 IPO at $28 per share and follows a previously announced 25% workforce reduction plan.

Icon Plc (NASDAQ: ICLR) shares plummeted 32.55% in premarket trading after disclosing an internal accounting investigation by its Audit Committee. The probe, which began in October 2025, focuses on revenue recognition practices from 2023-2025, with preliminary findings indicating revenue may have been overstated by less than 2% in each year. The company has withdrawn its 2025 guidance and delayed financial reporting, with results expected by April 30, 2026.

Trinity Street Asset Management completely exited its position in Axalta Coating Systems, selling 770,919 shares worth approximately $22.1 million. The exit represents a full liquidation of the fund's stake in the specialty coatings company. Trinity simultaneously increased its positions in higher-growth companies like Taiwan Semiconductor Manufacturing, suggesting the fund manager sees better growth prospects in the semiconductor and technology sectors compared to the slower-growing industrial coatings industry.

The global real world evidence (RWE) solutions market is projected to grow from $5.42 billion in 2025 to $10.83 billion by 2030, with a 14.8% CAGR, driven by value-based care, chronic disease prevalence, and advancements in healthcare data analytics.

Clinical research organization ICON reported better-than-expected Q2 financial results, with quarterly sales of $2.02 billion and adjusted earnings of $3.26 per share. The company raised its fiscal 2025 sales guidance and expanded its share buyback program to $1 billion.

The global regulatory affairs outsourcing market is expected to grow significantly from 2024 to 2030, driven by the globalization of biopharmaceutical and medical device companies and the need for specialized regulatory expertise. Technological advancements in regulatory processes are also shaping the market.

Faruqi & Faruqi, LLP is investigating potential claims against ICON plc for allegedly making false and/or misleading statements about its business and financial performance, leading to significant losses for investors.

Telix Pharmaceuticals Limited, a biopharmaceutical company, has appointed Anne Whitaker as a Non-Executive Director based in the United States. Whitaker is a seasoned healthcare leader with over 30 years of global corporate experience.

ICON plc, a healthcare company, is facing a class action lawsuit due to alleged failure to disclose material information during the class period, resulting in a significant revenue shortfall and stock price decline.